Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a positive outlook with strong product development, strategic focus on biosimilars, and promising pipeline assets like VESALIUS-CV and MariTide. Despite some unclear management responses, the emphasis on growth drivers, disciplined capital allocation, and innovative strategies in obesity and cardiovascular markets suggest a positive sentiment. The Q&A reveals enthusiasm for future opportunities and robust R&D investments, supporting a positive stock price movement.
Key Financial Performance
Revenue Revenues increased 12% year-over-year to $9.6 billion, driven by strong performance of six key growth drivers and discrete items like $250 million from favorable changes to U.S. estimated sales deductions and a $90 million government order for Nplate.
Volume Growth Volume grew 14% year-over-year, reflecting the strength of the portfolio and disciplined execution.
Non-GAAP Operating Margin Non-GAAP operating margin was 47%, reflecting significant investments across the business, including a 31% year-over-year growth in non-GAAP R&D spending.
Non-GAAP R&D Spending Non-GAAP R&D spending grew 31% year-over-year, driven by business development transactions and increased investment in the late-stage pipeline.
Free Cash Flow Generated $4.2 billion in free cash flow in the third quarter, reflecting operational momentum and rigorous management of working capital.
Debt Retirement $6.0 billion of debt retired in 2025, contributing to a return to pre-Horizon capital structure ahead of plan.
Tax Rate Non-GAAP tax rate increased 4.8 percentage points year-over-year to 18.2%, primarily due to the change in earnings mix.
Repatha Sales Repatha delivered $794 million in sales, up 40% year-over-year, driven by increased adoption and the launch of the AmgenNow direct-to-patient program.
EVENITY Sales EVENITY delivered $541 million in sales, up 36% year-over-year, driven by higher prescription volumes and increased market share in the bone builder segment.
Prolia Sales Prolia delivered $1.1 billion in sales, an increase of 9% year-over-year, though future sales are expected to be impacted by increased competition from biosimilars.
Rare Disease Portfolio Rare disease portfolio grew 13% year-over-year to $1.4 billion, driven by strong performance across products like UPLIZNA and TEPEZZA.
TEZSPIRE Sales TEZSPIRE sales increased 40% year-over-year to $377 million, driven by its differentiated profile and recent approval for additional indications.
Oncology Portfolio Innovative oncology portfolio grew 9% year-over-year to $2.3 billion, driven by products like IMDELLTRA and BLINCYTO.
Biosimilar Portfolio Biosimilar portfolio sales increased 52% year-over-year to $775 million, now annualizing at $3 billion, driven by new launches and strong adoption.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AmgenNow: A new direct-to-patient platform launched in the U.S. to provide access to Repatha at one of the lowest prices globally, enhancing affordability and access.
MariTide: Phase III studies for chronic weight management and cardiovascular conditions are fully enrolled, with additional studies in obstructive sleep apnea initiated.
Olpasiran: Event-driven Phase III cardiovascular outcome study is progressing, targeting Lp(a) to reduce cardiovascular events.
TEZSPIRE: Approved for chronic rhinosinusitis with nasal polyps and enrolling patients for COPD studies. Achieved over $1 billion in sales year-to-date, with strong growth in severe uncontrolled asthma and new indications.
IMDELLTRA: Established as standard of care in second-line small cell lung cancer with promising survival data in combination therapies.
BLINCYTO: Initiated a study for subcutaneous administration in relapsed/refractory B-ALL.
Xaluritamig: Advancing in Phase III studies for metastatic castrate-resistant prostate cancer.
Repatha: Sales increased 40% year-over-year, now annualizing at $3 billion. Significant opportunity exists with 100 million people needing LDL-C lowering.
EVENITY: Sales grew 36% year-over-year, with significant untapped potential in the U.S. and Japan.
Biosimilar Portfolio: Sales increased 52% year-over-year, annualizing at $3 billion, with new launches driving growth.
Manufacturing Investments: Over $3 billion planned investments in the U.S. in 2025, building on $40 billion since 2017.
AI and Technology: Accelerating molecule design, trial enrollment, and manufacturing optimization using AI.
Debt Management: $6 billion of debt retired in 2025, returning to pre-Horizon capital structure ahead of plan.
Policy Engagement: Engaging with policymakers to improve access, protect innovation, and strengthen the biomanufacturing ecosystem.
Pipeline Expansion: Focused on advancing late-stage programs like MariTide, Olpasiran, and Xaluritamig for long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Declining Selling Prices: The company is experiencing declining selling prices across the industry, which could impact revenue growth despite volume increases.
Generic Competition: The introduction of a generic competitor for RAVICTI in the rare disease portfolio is expected to negatively impact sales.
Increased Competition for Prolia: Three biosimilars have launched in the U.S., and increased competition is expected to negatively impact Prolia sales in future quarters.
Regulatory and Tariff Risks: The guidance includes the estimated impact of implemented tariffs but does not account for tariffs or pricing actions announced but not yet implemented, creating uncertainty.
Supply Chain and Manufacturing Investments: Significant investments in manufacturing and R&D are required to meet growing global demand, which could strain resources and budgets.
Unmet Potential in Key Markets: Products like Repatha and EVENITY have significant untapped potential, but underutilization and low treatment rates pose challenges to realizing full market potential.
Clinical Trial Risks: The OCEAN(a) Phase III cardiovascular outcome study for Olpasiran is progressing slower than initial predictions, which could delay results and impact timelines.
Efficacy Concerns in Oncology: The FORTITUDE-102 study for bemarituzumab in gastric cancer was stopped due to inadequate efficacy, raising concerns about the success of certain oncology programs.
Economic and Financial Risks: The company has significant debt obligations, although progress has been made in retiring debt. Changes in tax rates and earnings mix also pose financial risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Amgen has raised its 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, reflecting strong portfolio performance and business momentum.
Non-GAAP Earnings Per Share (EPS) Guidance for 2025: The company expects non-GAAP EPS to be between $20.60 and $21.40 for 2025.
Capital Expenditures for 2025: Amgen anticipates capital expenditures of approximately $2.2 billion to $2.3 billion in 2025, aimed at expanding network capacity for its product portfolio and innovative pipeline.
Non-GAAP R&D Expenses for 2025: Non-GAAP R&D expenses are expected to grow at a mid-20s percentage rate year-over-year in 2025, driven by increased investment in late-stage programs and business development transactions.
Non-GAAP Tax Rate for 2025: The company projects a non-GAAP tax rate in the range of 15.0% to 16.5% for 2025.
Free Cash Flow: Amgen generated $4.2 billion in free cash flow in Q3 2025, reflecting operational momentum and rigorous management of working capital.
Pipeline and Product Development: Amgen is advancing late-stage programs, including MariTide, Olpasiran, Xaluritamig, and rare disease treatments, which are expected to drive sustainable long-term growth.
AI and Technology Investments: The company is accelerating investments in AI and technology across the value chain, including trial enrollment, manufacturing optimization, and customer engagement.
Biosimilar Portfolio: Amgen's biosimilar portfolio is annualizing at $3 billion in sales, with additional launches expected to provide meaningful top-line growth and durable cash flow.
TEZSPIRE Expansion: TEZSPIRE has been approved for additional indications, including chronic rhinosinusitis with nasal polyps, and is expected to help a broader patient population.
MariTide Phase III Studies: Amgen is conducting six global Phase III studies for MariTide, targeting obesity, cardiovascular disease, and obstructive sleep apnea, with robust enrollment and evidence generation.
Olpasiran Phase III Study: The OCEAN(a) Phase III cardiovascular outcome study for Olpasiran is fully enrolled, with updates on primary analysis timing to be provided as the study matures.
UPLIZNA Approvals and Indications: UPLIZNA is progressing toward approval for generalized myasthenia gravis and has shown potential across a spectrum of IgG4-related disease patients.
IMDELLTRA and BLINCYTO Oncology Advances: Amgen is advancing its bispecific T cell engager platform, with IMDELLTRA and BLINCYTO showing strong clinical results and expanding indications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payments: In addition to the increase of 31% in non-GAAP R&D described above, we continue to advance and accelerate technology and AI across the value chain from discovery to development to manufacturing and through to commercial execution. For 2025, we now expect capital expenditures of roughly $2.2 billion to $2.3 billion to expand network capacity for our products across the portfolio and our innovative pipeline, including MariTide. Our capital expenditures reflect significant investments across the United States, including Ohio, North Carolina, Puerto Rico, Rhode Island, California and Massachusetts. We expect our projects to continue to be on budget and on time. In addition, we returned capital to shareholders through competitive dividend payments of $2.38 per share, representing a 6% increase compared to the third quarter of 2024.
Share Repurchase: We continue to strengthen our balance sheet with $4.5 billion of debt retired in 2024 and $6.0 billion of debt retired in 2025. We are pleased to report that we have returned to our pre-Horizon capital structure ahead of plan, and we will achieve greater than $500 million in pretax cost synergies in 2025 in connection with the acquisition.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With Olpasiran, you mentioned best-in-class in the context of a competitive landscape out there. Could you speak to your confidence in this program and what the event rate means for a base case readout, whether it's now in 2027 versus year-end '26 prior?
A:James Bradner expressed strong conviction in Olpasiran, citing its genetic association with cardiovascular disease, its best-in-class properties, and clean safety profile. He noted that the OCEAN(a) study is event-driven and did not provide a specific readout date but assured updates as the study progresses.
Q:From a BD perspective, you spoke to how you're back at pre-Horizon debt levels. How does this impact your approach to business development heading into 2026?
A:Robert Bradway stated that returning to pre-Horizon debt levels does not significantly affect their business development strategy. The company remains focused on earlier-stage opportunities in therapeutic areas of interest.
Q:Can you walk us through some of the puts and takes that we should think about heading into 2026?
A:Peter Griffith highlighted key growth drivers such as Repatha, EVENITY, TEZSPIRE, and biosimilars. He emphasized disciplined capital allocation, continued investment in R&D, and achieving industry-leading margins. He noted no incremental step change in R&D expenses is expected and mentioned completed and ongoing studies that will influence 2026.
Q:Just one clarification on ROCKET ASTRO. I noticed you completed that trial and it said the safety was consistent. Were there any gastrointestinal ulcerations in that study?
A:James Bradner confirmed that the ROCKET ASTRO study met its co-primary endpoints and observed mild gastrointestinal side effects, consistent with prior studies, but not at an excessive rate.
Q:We're curious about the VESALIUS-CV results and how you expect them to impact the overall market opportunity for Repatha? And also what should we look for in the details when you present them at AHA?
A:James Bradner and Murdo Gordon emphasized the importance of VESALIUS-CV in preventing first cardiovascular events, a first for PCSK9 inhibitors. They highlighted the study's dual primary endpoint success and its potential to improve lipid management globally. They encouraged attention to the upcoming AHA presentation.
Q:FDA recently released new biosimilar guidance and maybe removing the need for comparative efficacy studies. Does that change your view on the business?
A:Murdo Gordon stated that the new guidance does not change Amgen's strategic focus on biosimilars. He emphasized their competitive position and innovative development capabilities, citing the success of their EYLEA biosimilar.
Q:The second year of the MariTide data is expected by year-end. Can you give us any sense of what to expect and put it in context?
A:James Bradner explained that Part 2 of the MariTide study focuses on maintenance strategies, testing different dosing regimens. He noted that the study is not powered for significant insights into weight loss but will inform Phase III designs and maintenance strategies.
Q:What is Amgen's latest view on the obesity market and the company's role within the market with MariTide and the broader pipeline?
A:Robert Bradway, James Bradner, and Murdo Gordon expressed enthusiasm for the obesity market, highlighting MariTide's differentiated profile and potential for less frequent dosing. They emphasized Amgen's long-term commitment to addressing obesity with a robust pipeline, including oral and injectable assets.
Q:Can you highlight what you think needs to change from a policy perspective to encourage even more uptake of biosimilars?
A:Robert Bradway noted that the biosimilar market is performing well but highlighted differences between Part B and Part D medicines. He emphasized the importance of maintaining current policies to avoid issues seen in the generic drug market.
Q:There is some confusion on whether we'll get two-year weight loss data in the upcoming Part 2 readout of the MariTide obesity Phase II trial. Can you clarify the design?
A:James Bradner clarified that Part 2 of the MariTide study is a maintenance study testing different dosing regimens. He noted that patients achieving significant weight loss in Part 1 were randomized into Part 2, and the study is designed to inform maintenance strategies rather than provide significant weight loss insights.
Q:Can you talk about the strong performance of UPLIZNA in IgG4-related disease and your views on the sales opportunity?
A:Murdo Gordon highlighted the early success of UPLIZNA in IgG4-related disease, noting its efficacy in reducing flares and steroid use. He mentioned the potential for market expansion due to increased awareness and the unique FDA-approved status of UPLIZNA for this condition.
Q:What are the top two or three pipeline cards that could be most impactful for Amgen in the next 6 to 12 months?
A:James Bradner highlighted the VESALIUS-CV study, IMDELLTRA, and tarlatamab as key pipeline assets. He emphasized their potential to address significant unmet needs and deliver meaningful clinical outcomes.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the readout date for the OCEAN(a) study, stating they would keep stakeholders updated as the study progresses. Additionally, they did not provide detailed insights into the two-year weight loss data for the MariTide study, emphasizing its design to inform maintenance strategies rather than weight loss outcomes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BLINCYTO
EVENITY
III study
IMDELLTRA
MariTide
Phase III
RD
Repatha
TEZSPIRE
UPLIZNA
VESALIUS CV
addition
attack stroke
bone
cell lung
chemotherapy
combination
date
development
heart attack
investment
launch
line
lipid
lung cancer
patient
potential
product
program
rate
result
risk
sale
stage
standard care
term
therapy
treatment
trial
world
AMGN Transcript
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-4
Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call summary shows positive financial performance with revenue, operating margin, net income, and EPS all increasing year-over-year. However, the lack of discussion on strategic initiatives, operational updates, risks, and returns limits the ability to assess future growth and potential risks. The Q&A section does not provide additional insights. Without more information on strategic direction or market sentiment, the prediction remains neutral.
AMGN Slides
AMGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
